These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19779880)

  • 1. Role of hematopoietic stem cell transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
    Tallman MS; Mathews V; DiPersio JF
    Cancer Treat Res; 2009; 144():415-39. PubMed ID: 19779880
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
    de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
    Haematologica; 2006 Jun; 91(6):750-6. PubMed ID: 16769576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
    Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
    Valcárcel D; Martino R
    Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
    Strodtbeck D; Bornhäuser M; Hänel M; Lerche L; Schaich M; Illmer T; Thiede C; Geissler G; Herbst R; Ehninger G; Platzbecker U
    Bone Marrow Transplant; 2005 Dec; 36(12):1083-8. PubMed ID: 16247435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem cell transplantation in myelodysplastic syndromes.
    de Witte T; Suciu S; Brand R; Muus P; Kröger N
    Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome.
    Russell JA; Larratt L; Brown C; Turner AR; Chaudhry A; Booth K; Woodman RC; Wolff J; Valentine K; Stewart D; Ruether JD; Ruether BA; Klassen J; Jones AR; Gyonyor E; Egeler M; Dunsmore J; Desai S; Coppes MJ; Bowen T; Anderson R; Poon MC
    Bone Marrow Transplant; 1999 Dec; 24(11):1177-83. PubMed ID: 10642805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation for advanced acute myeloid leukemia.
    Linker CA; Damon LE; Ries CA; Navarro WA; Case D; Wolf JL
    Bone Marrow Transplant; 2002 Feb; 29(4):297-301. PubMed ID: 11896426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
    de Lima M; Giralt S
    Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
    Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Sill H; Zinke-Cerwenka W; Berghold A
    Bone Marrow Transplant; 2007 Apr; 39(8):509; author reply 509-10. PubMed ID: 17322936
    [No Abstract]   [Full Text] [Related]  

  • 15. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
    Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods.
    Testoni N; Lemoli RM; Martinelli G; Carboni C; Pelliconi S; Ottaviani E; Ruggeri D; Rizzi S; Motta MR; Visani G; Tura S
    Bone Marrow Transplant; 1998 Dec; 22(11):1065-70. PubMed ID: 9877268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
    Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
    Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemopoietic cell transplantation for the myelodysplastic syndromes.
    Scott BL; Deeg HJ
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.